{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:08:23Z","timestamp":1789715303509,"version":"4.0.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jtho.2017.03.018","type":"journal-article","created":{"date-parts":[[2017,4,20]],"date-time":"2017-04-20T18:59:56Z","timestamp":1492714796000},"page":"778-781","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?"],"prefix":"10.1016","volume":"12","author":[{"given":"Sylvie","family":"Lantuejoul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolwenn","family":"Le Stang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Damiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Scherpereel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Galateau-Sall\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2017.03.018_bib1","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: new opportunity for mesothelioma treatment?","volume":"41","author":"Marcq","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2017.03.018_bib2","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.jtho.2017.03.018_bib3","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.302","article-title":"Long-term overall survival for patients with malignant pleural mesothelioma on pembrolizumab enrolled in KEYNOTE-028","volume":"12","author":"Alley","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2017.03.018_bib4","doi-asserted-by":"crossref","first-page":"S292","DOI":"10.1016\/j.jtho.2016.11.300","article-title":"A\u00a0phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with translational research (TR) biopsies","volume":"12","author":"Quispel-Janssen","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib5","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/annonc\/mdw181","article-title":"Biomarkers associated with checkpoint inhibitors","volume":"27","author":"Manson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.jtho.2017.02.013","article-title":"The immune microenvironment, genome-wide copy number aberrations and survival in mesothelioma","volume":"12","author":"Thapa","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jamaoncol.2016.3015","article-title":"A quantitative comparison of antibodies to programmed cell death 1 ligand1","volume":"3","author":"Gaule","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","article-title":"PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","volume":"12","author":"Hirsch","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/modpathol.2016.117","article-title":"Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas","volume":"29","author":"Scheel","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2017.03.018_bib10","doi-asserted-by":"crossref","unstructured":"Rimm DL, Han G, Taube JM, et\u00a0al. A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer [e-pub ahead of print]. JAMA\u00a0Oncol. http:\/\/dx.doi.org\/10.1001\/jamaoncol.2017.0013, accessed March 30, 2017.","DOI":"10.1001\/jamaoncol.2017.0013"},{"key":"10.1016\/j.jtho.2017.03.018_bib11","doi-asserted-by":"crossref","unstructured":"Ratcliffe MJ, Sharpe A, Midha A, et\u00a0al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer [e-pub ahead of print]. Clin Cancer Res. http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-16-2375, accessed March 30, 2017.","DOI":"10.1158\/1078-0432.CCR-16-2375"},{"key":"10.1016\/j.jtho.2017.03.018_bib12","doi-asserted-by":"crossref","unstructured":"Adam J, Rouquette I, Damotte D, et\u00a0al. Multicentric French Harmonization Study for PD-L1 IHC Testing in NSCLC. Abstract presented at: 17th World Conference on Lung Cancer. December 4\u20137, 2016; Vienna, Austria.","DOI":"10.1016\/j.jtho.2016.11.013"},{"key":"10.1016\/j.jtho.2017.03.018_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study\u00a0of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtho.2017.03.018_bib14","doi-asserted-by":"crossref","first-page":"S294","DOI":"10.1016\/j.jtho.2016.11.303","article-title":"Somatic genetic alterations and immune microenvironment in malignant pleural mesothelioma","volume":"12","author":"Vigneswaran","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib15","doi-asserted-by":"crossref","first-page":"E1046","DOI":"10.3390\/ijms17071046","article-title":"PD-L1 immunohistochemical detection in tumor cells and tumor microenvironment: main considerations on the use of tissue micro arrays","volume":"17","author":"Botti","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2017.03.018_bib16","doi-asserted-by":"crossref","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedres","year":"2015","journal-title":"PLOS One"},{"key":"10.1016\/j.jtho.2017.03.018_bib17","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2016.01.010","article-title":"Immune biomarkers PD-1\/PD-L1 and TLR3 in malignant\u00a0pleural mesotheliomas","volume":"52","author":"Combaz-Lair","year":"2016","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2017.03.018_bib19","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.jtho.2016.07.033","article-title":"Malignant mesothelioma effusions are infiltrated by CD3+ T cells highly expressing PD-L1 and the PD-L1+ tumor cells within these effusions are susceptible to ADCC by the anti-PD-L1 antibody avelumab","volume":"11","author":"Khanna","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2017.03.018_bib20","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2017.03.018_bib21","doi-asserted-by":"crossref","first-page":"E739","DOI":"10.3390\/ijms17050739","article-title":"A\u00a0tumor-specific neo-antigen caused by a frameshift mutation in BAP1 is a potential personalized biomarker in malignant peritoneal mesothelioma","volume":"17","author":"Lai","year":"2016","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417302228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086417302228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T10:55:33Z","timestamp":1535885733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086417302228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1556086417302228"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2017.03.018","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2017.02.013","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}